新型大环内酯类抗生素制剂TMS - 19 - Q.O片在口腔外科领域的临床研究
[Clinical studies on TMS-19-Q.O tablets, the preparation of a new macrolide antibiotic, in the field of oral surgery].
作者信息
Sasaki J, Yamada Y, Takai H, Ohmura H, Abe H, Shiki K, Narita Y, Michi K, Ohno K, Kawanishi I
出版信息
Jpn J Antibiot. 1985 Mar;38(3):615-33.
Multicenter clinical trial or TMS-19-Q.O tablet was performed to evaluate the usefulness in oral surgery. The results obtained were as follows: Clinical efficacy was assessed by clinical points. The patients entered into the trial were 77 cases with periodontitis, 23 with pericoronitis, 92 with osteitis of jaw and 18 with other infections, and the each effective rates were 80.5, 60.9, 83.7 and 72.2%, respectively. Overall effective rate was 79.0%. Isolation frequency of organisms were 33.8% in periodontitis, 34.8% in osteitis of jaw and 17.4% in pericoronitis. Bacteria isolated were aerobic organisms (63.1%) and anaerobic organisms (36.9%). TMS-19-Q.O tablet was well tolerated, and no adverse reaction was observed.
进行了一项关于TMS - 19 - Q.O片剂的多中心临床试验，以评估其在口腔外科手术中的效用。获得的结果如下：临床疗效通过临床评分进行评估。纳入试验的患者中，牙周炎患者77例，冠周炎患者23例，颌骨骨炎患者92例，其他感染患者18例，各自的有效率分别为80.5%、60.9%、83.7%和72.2%。总有效率为79.0%。微生物的分离频率在牙周炎中为33.8%，在颌骨骨炎中为34.8%，在冠周炎中为17.4%。分离出的细菌为需氧菌（63.1%）和厌氧菌（36.9%）。TMS - 19 - Q.O片剂耐受性良好，未观察到不良反应。
Zotero 插件